Comparative Pharmacology
Head-to-head clinical analysis: AMINOCAPROIC ACID versus LYSTEDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOCAPROIC ACID versus LYSTEDA.
AMINOCAPROIC ACID vs LYSTEDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibition of plasminogen activation, reducing fibrinolysis by binding to plasminogen and blocking its conversion to plasmin.
Competitive inhibition of plasminogen activation, reducing fibrinolysis.
Loading dose: 4-5 g intravenously (IV) over 1 hour, followed by continuous IV infusion of 1 g/hour for 8 hours or until bleeding controlled. Oral: 1 g every hour for 8 hours, then 1 g every 2 hours for 8 additional hours.
650 mg orally three times daily (total 3.9 g/day) for up to 5 days during menses.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1-3 hours) in patients with normal renal function. Prolonged in renal impairment (up to 20 hours in anuria).
Clinical Note
moderateAminocaproic acid + Tretinoin
"Aminocaproic acid may increase the thrombogenic activities of Tretinoin."
Terminal elimination half-life is approximately 2 hours (range 1.5–2.5 hours). In patients with renal impairment, half-life is significantly prolonged (up to 20 hours in severe renal impairment).
Primarily renal (80-90% unchanged). A small fraction (<5%) is excreted as metabolites. No significant biliary/fecal elimination.
Primarily renal excretion (>95% unchanged drug via glomerular filtration). Less than 5% is metabolized (mainly acylated derivative).
Category C
Category C
Antifibrinolytic
Antifibrinolytic